


FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				053466/0299	
				09/762550	
INTERNATIONAL APPLICATION NO. PCT/JP99/04533		INTERNATIONAL FILING DATE August 23, 1999		U.S. APPLICATION NO. (If known, 35 U.S.C. 371(c)(1)) Unassigned PRIORITY DATE CLAIMED August 24, 1998	
TITLE OF INVENTION A PREVENTIVE OR THERAPEUTIC AGENT FOR PANCREATITIS COMPRISING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT					
APPLICANT(S) FOR DO/EO/US Akihiro FUNAKOSHI and Kyoko MIYASAKA.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1.	<input checked="" type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2.	<input type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3.	<input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4.	<input checked="" type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.			
5.	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
	<input type="checkbox"/>	is transmitted herewith (required only if not transmitted by the International Bureau).			
	<input checked="" type="checkbox"/>	has been transmitted by the International Bureau.			
	<input type="checkbox"/>	is not required, as the application was filed in the United States Receiving Office (RO/US)			
6.	<input checked="" type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
	<input checked="" type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
	<input type="checkbox"/>	are transmitted herewith (required only if not transmitted by the International Bureau).			
	<input type="checkbox"/>	have been transmitted by the International Bureau.			
	<input type="checkbox"/>	have not been made; however, the time limit for making such amendments has NOT expired.			
	<input checked="" type="checkbox"/>	have not been made and will not be made.			
8.	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9.	<input checked="" type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10.	<input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
11.	<input type="checkbox"/>	Applicant claims small entity status under 37 CFR 1.27.			
Items 12. to 17. below concern other document(s) or information included:					
12.	<input type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
13.	<input checked="" type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
14.	<input checked="" type="checkbox"/>	A FIRST preliminary amendment.			
	<input type="checkbox"/>	A SECOND or SUBSEQUENT preliminary amendment.			
15.	<input type="checkbox"/>	A substitute specification.			
16.	<input type="checkbox"/>	A change of power of attorney and/or address letter.			
17.	<input checked="" type="checkbox"/>	Other items or information: Associate Power of Attorney.			



23533

PATENT TRADEMARK OFFICE

U.S. APPLICATION NO. <b>097762550</b> Unassigned		INTERNATIONAL APPLICATION NO. PCT/JP99/04533		ATTORNEY'S DOCKET NUMBER 053466/0299	
18. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$860.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$690.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$710.00					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....\$1,000.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))					
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	26	- 20	= 6	x \$18.00	\$108.00
Independent Claims	6	- 3	= 3	x \$80.00	\$240.00
Multiple dependent claim(s) (if applicable)				\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$1208.00	
Reduction by 1/2 for filing by small entity, if applicable.				\$0.00	
SUBTOTAL =				\$1208.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
TOTAL NATIONAL FEE =				\$1208.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$40.00	
TOTAL FEES ENCLOSED =				\$1248.00	
				Amount to be: refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$1,248.00</u> to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Foley & Lardner 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109			 SIGNATURE NAME STEPHEN B. MAEBIUS REGISTRATION NUMBER 35,264		

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Attorney Docket No. 053466/0299**

In re patent application of

Akihiro Funakoshi et al.

Serial No. Unassigned

Filed: February 9, 2001

For: A PREVENTIVE OR THERAPEUTIC AGENT FOR PANCREATITIS  
COMPRISING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT**PRELIMINARY AMENDMENT**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the present application, Applicants respectfully request that the above-identified application be amended as follows:

**IN THE CLAIMS:**

Please cancel claims 27-39 without prejudice or disclaimer of the subject matter thereof.

Please amend the following claims:

Claim 6, line 2, delete "any of claims 2 to 5" and insert --claim 2--.

Claim 9, line 2, delete "any of claims 2 to 4" and insert --claim 2--.

Claim 11, line 2, delete "any of claims 1 to 10" and insert --claim 1--.

Serial No. To be assigned

**REMARKS**

Applicant respectfully requests that the foregoing amendments be made prior to examination of the present application.

Respectfully submitted,

February 9, 2001  
Date

Stephen B. Maebius  
Stephen B. Maebius  
Registration No. 35,264

FOLEY & LARDNER  
3000 K Street, N.W., Suite 500  
Washington, D. C. 20007-5109  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

4/PRTS

- 1 -

## SPECIFICATION

A PREVENTIVE OR THERAPEUTIC AGENT FOR PANCREATITIS  
COMPRISING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT

5

## Technical Field

The present invention relates to a preventive or therapeutic agent for pancreatitis comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

10

## Background Art

IL-6 is a cytokine which is also called B cell stimulating factor 2 (BSF2) or interleukin  $\beta$ 2. IL-6 was discovered as a differentiation factor involved in the activation of B-lymphatic cells (Hirano, T. et al., Nature (1986) 324, 73-76). Thereafter, it was found to be a multifunctional cytokine that influences various functions of cells (Akira, S. et al., Adv. in Immunology (1993) 54, 1-78). IL-6 has been reported to induce the maturation of T-lymphatic cells (Lotz, M. et al., J. Exp. Immunol. (1988) 167, 1253-1258).

20

IL-6 transmits its biological activity through two types of proteins on the cell. One is IL-6 receptor, a ligand-binding protein with a molecular weight of about 80 kD, to which IL-6 binds (Taga, T. et al., J. Exp. Med. (1987) 166, 967-981; Yamasaki, K. et al., Science (1987) 241, 825-828). IL-6 receptor occurs not only in the membrane-bound form that penetrates through and is expressed on the cell membrane but also as a soluble IL-6 receptor consisting mainly of the extracellular region.

25

30

The other is a membrane-bound protein gp130 having a molecular weight of about 130 kD that is involved in non-ligand-binding signal transduction. IL-6 and IL-6 receptor form the IL-6/IL-6 receptor complex, which, after binding to gp130, transmits its biological activity to the cell (Taga, T. et al., Cell (1989) 58, 573-581).

35

An IL-6 antagonist is a substance that inhibits the

09762550.020001

transduction of biological activity of IL-6. As the IL-6 antagonist, there have been known so far antibody directed against IL-6 (anti-IL-6 antibody), antibody directed against IL-6 receptor (anti-IL-6 receptor antibody), and antibody directed against gp130 (anti-gp130 antibody), altered IL-6, partial peptides of IL-6 or IL-6 receptor and the like.

Anti-IL-6 receptor antibody has been described in several reports (Novick D. et al., Hybridoma (1991) 10, 137-146, Huang, Y. W. et al., Hybridoma (1993) 12, 621-630, International Patent Publication WO 95-09873, French Patent Application FR 2694767, United States Patent US 521628). Humanized PM-1 antibody has been known that was obtained by grafting the complementarity determining region (CDR) of one of them, a mouse antibody PM-1 (Hirata, Y. et al., J. Immunology (1989) 143, 2900-2906), to a human antibody (the International Patent Publication WO 92-19759).

Pancreatitis is an inflammatory disease in which the activation of pancreatic enzymes causes autolysis in pancreatic tissues. There have been reported that the amount of IL-6 produced in the peripheral blood mononuclear cells is significantly high in patients with pancreatitis as compared to healthy normal humans, and that IL-6 production from the peripheral blood mononuclear cells is high in cases of acute pancreatitis with systemic complications as compared to those with no complications (de Beaux A. C. et al., Brit. J. Surgery, 83, 1071-5, 1996). Furthermore, since blood levels of IL-6 are higher and respond earlier than other parameters in severe cases of acute pancreatitis, they have been considered to be a prognostic indicator for severity of pancreatitis (Inagaki, T. et al., Pancreas, 14, 1-8, 1997).

It has been suggested that IL-1 and TNF closely correlate with the disease states, and mice lacking receptors to both of the cytokines do not suffer serious

disease conditions, and show markedly decreased mortality rate (Denham, W. et al., Gastroenterology, 113, 1741-6, 1997). Attempts have been made to treat pancreatitis using these inhibitors in animal models (Norman, J. et al., Surgery, 117, 648-6755, 1995, Hughes, C. B. et al., American J. Surgery, 171, 274-280, 1996, Norman, J. et al., surgery, 120, 515-621, 1996).

However, no attempts have been made to specifically suppress the biological activity of IL-6 using IL-6 antagonists such as anti-IL-6 receptor antibody in pancreatitis, and it was unknown that IL-6 antagonists such as anti-IL-6 receptor antibody exhibit therapeutic effects on pancreatitis.

#### Disclosure of the Invention

It is an object of the present invention to provide a preventive or therapeutic agent for pancreatitis said agent being free of the above-mentioned drawbacks.

Thus, the present invention provides (1) a preventive or therapeutic agent for pancreatitis comprising an IL-6 antagonist as an active ingredient.

The present invention also provides (2) a preventive or therapeutic agent for pancreatitis comprising an antibody directed against IL-6 receptor as an active ingredient.

The present invention also provides (3) a preventive or therapeutic agent for pancreatitis comprising a monoclonal antibody directed against IL-6 receptor as an active ingredient.

The present invention also provides (4) a preventive or therapeutic agent for pancreatitis comprising a monoclonal antibody directed against human IL-6 receptor as an active ingredient. The monoclonal antibody directed against human IL-6 receptor is preferably PM-1 antibody.

The present invention also provides (5) a preventive or therapeutic agent for pancreatitis comprising a

monoclonal antibody directed against mouse IL-6 receptor as an active ingredient. The monoclonal antibody directed against mouse IL-6 receptor is preferably MR16-1 antibody.

5       The present invention also provides (6) a preventive or therapeutic agent for pancreatitis comprising a recombinant antibody directed against IL-6 receptor as an active ingredient. The recombinant antibody directed against IL-6 receptor has preferably a human antibody  
10       constant region (C region).

      The present invention also provides (7) a preventive or therapeutic agent for pancreatitis comprising a chimeric or humanized antibody directed against IL-6 receptor as an active ingredient.

15       The present invention also provides (8) a preventive or therapeutic agent for pancreatitis comprising humanized PM-1 antibody as an active ingredient.

      The present invention also provides (9) a preventive or therapeutic agent for acute or chronic pancreatitis  
20       comprising the IL-6 antagonist described in the above (1) to (8) as an active ingredient. Acute or chronic pancreatitis is, for example, severe or mild pancreatitis.

      The present invention also provides (10) an agent  
25       for suppressing pancreatic edema, said agent comprising the IL-6 antagonist described in the above (1) to (8) as an active ingredient.

      The present invention also provides (11) an agent  
30       for suppressing pancreatic edema, said agent comprising an antibody directed against IL-6 receptor described in the above (3) to (8) as an active ingredient.

#### Brief Description of the Drawings

35       Figure 1 shows that caerulein administration causes pancreatic edema resulting in the increased weight of the pancreas in IL-6 transgenic mice as compared to normal mice. It also shows that the above effect is suppressed

09762550.020001



by the administration of anti-IL-6 antibody.

Figure 2 is a micrograph of the pancreatic tissue of a normal mouse that developed acute pancreatitis by caerulein administration.

5        Figure 3 is a micrograph of the pancreatic tissue of an IL-6 transgenic mouse that developed acute pancreatitis by caerulein administration.

10        Figure 4 is a micrograph of the pancreatic tissue of an IL-6 transgenic mouse that developed acute pancreatitis by caerulein administration and that received MR16-1 as well. As compared to the caerulein-induced pancreatitis in the normal mouse in Figure 2, the caerulein-induced pancreatitis is aggravated (thus, enhanced edema in the interstitial tissue and enhanced  
15        infiltration in inflammatory cells) in the IL-6 transgenic mouse in Figure 3. In Figure 4, in contrast, the aggravation has been suppressed by the administration of an anti-IL-6 receptor antibody MR16-1.

20        Figure 5 shows that the increase in the weight of the pancreas in an IL-6 transgenic mouse induced by the administration of LPS and caerulein can be suppressed by the administration of an anti-IL-6 receptor antibody.

#### Best Mode for Carrying Out the Invention

25        IL-6 antagonists for use in the present invention may be of any origin, any kind, and any form, as long as they have a preventive or therapeutic effect for pancreatitis, or an effect of controlling pancreatic edema.

30        IL-6 antagonists block signal transduction by IL-6 and inhibit the biological activity of IL-6. Preferably, IL-6 antagonists have an activity of inhibiting the binding of any of IL-6, IL-6 receptor, and gp130. As the IL-6 antagonists, there can be mentioned preferably anti-  
35        IL-6 antibody, anti-IL-6 receptor antibody, anti-gp130 antibody, altered IL-6, altered soluble IL-6 receptor, a partial peptide of IL-6 or IL-6 receptor, and low

molecular weight substances having the same activity as these.

Anti-IL-6 antibodies for use in the present invention can be obtained as polyclonal or monoclonal antibodies using a known method. As the anti-IL-6 antibodies for use in the present invention, monoclonal antibodies of, in particular, a mammalian origin, are preferred. Monoclonal antibodies of a mammalian origin include those produced by a hybridoma and those produced by a host which has been transformed with an expression vector containing genetically engineered antibody genes. These antibodies, via binding to IL-6, block the binding of IL-6 to IL-6 receptor and, thereby, block signal transduction of the biological activity of IL-6 into the cell.

Examples of such antibodies include MH166 (Matsuda et al., Eur. J. Immunol. (1988) 18, 951-956) and SK2 antibody (Sato, K. et al., The 21st Nihon Mennekigakkai Soukai (General Meeting of the Japan Immunology Society), Academic Record (1991) 21, 166) and the like.

An anti-IL-6 antibody-producing hybridoma can be basically constructed using a known procedure as described below. Thus, IL-6 may be used as a sensitizing antigen and is immunized in the conventional method of immunization. The immune cells thus obtained are fused with known parent cells in the conventional cell fusion process, and then monoclonal antibody-producing cells are screened by the conventional screening method to prepare the desired hybridoma.

Specifically, anti-IL-6 antibody may be obtained in the following manner. For example, a human IL-6 for use as the sensitizing antigen to obtain antibody can be obtained using the IL-6 gene/amino acid sequence disclosed in Eur. J. Biochem (1987) 168, 543-550, J. Immunol. (1988) 140, 1534-1541, or Agr. Biol. Chem. (1990) 54, 2685-2688.

After a suitable host cell is transformed by

00762550-020001

inserting the IL-6 gene sequence into a known expression vector system, the IL-6 protein of interest is purified from the host cell or the culture supernatant thereof by a known method, and the purified IL-6 protein can be used as the sensitizing antigen. Alternatively, a fusion protein of the IL-6 protein and another protein may be used as the sensitizing antigen.

Anti-IL-6 receptor antibodies for use in the present invention can be obtained as polyclonal or monoclonal antibodies using a known method. As the anti-IL-6 antibodies for use in the present invention, monoclonal antibodies of, in particular, a mammalian origin, are preferred. Monoclonal antibodies of a mammalian origin include those produced by a hybridoma and those produced by a host which has been transformed with an expression vector containing genetically engineered antibody genes. The antibodies, via binding to IL-6 receptor, inhibit the binding of IL-6 to IL-6 receptor, and thereby block the transduction of the biological activity of IL-6 into the cell.

Examples of such antibodies include MR16-1 antibody (Tamura, T., et al., Proc. Natl. Acad. Sci. USA (1993) 90, 11924-11928), PM-1 antibody (Hirata, et al., J. Immunology (1989) 143, 2900-2906), or AUK12-20 antibody, AUK64-7 antibody or AUK146-15 antibody (International Patent Publication WO 92-19759), and the like. Among them, PM-1 antibody is most preferred.

Incidentally, the hybridoma cell line which produces PM-1 antibody has been internationally deposited under the provisions of the Budapest Treaty as PM-1 on July 10, 1990 with the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, of 1-3, Higashi 1-chome, Tsukuba city, Ibaraki pref., Japan, as FERM BP-2998. The hybridoma cell line which produces MR16-1 antibody has been internationally deposited under the provisions of the Budapest Treaty as MR16-1 on March 13, 1997 with the National Institute of

Bioscience and Human Technology, Agency of Industrial Science and Technology, of 1-3, Higashi 1-chome, Tsukuba city, Ibaraki pref., Japan, as FERM BP-5875.

Hybridomas producing anti-IL-6 receptor monoclonal antibody can be basically prepared using a known procedure as described bellow. Thus, IL-6 receptor is used as a sensitizing antigen and is immunized according to the conventional method of immunization. The immune cells thus obtained are fused with known parent cells in the conventional cell fusion process, and then monoclonal antibody-producing cells may be screened by the conventional screening method to prepare the desired hybridoma.

Specifically, anti-IL-6 receptor antibody may be prepared in the following manner. For example, human IL-6 receptor used as the sensitizing antigen for obtaining antibody can be obtained using the IL-6 receptor gene sequence/amino acid sequence disclosed in European Patent Application EP 325474, and mouse IL-6 receptor can be obtained using that disclosed in Japanese Unexamined Patent Publication (Kokai) 3(1991)-155795.

There are two types of IL-6 receptor proteins: IL-6 receptor expressed on the cell membrane, and IL-6 receptor detached from the cell membrane (soluble IL-6 receptor) (Yasukawa et al., J. Biochem. (1990) 108, 673-676). Soluble IL-6 receptor antibody is composed substantially of the extracellular region of the IL-6 receptor bound to the cell membrane, and thereby is different from the membrane-bound IL-6 receptor in that the latter lacks the transmembrane region or both of the transmembrane region and the intracellular region. As the IL-6 receptor protein, any IL-6 receptor can be used, as long as it can be used a sensitizing antigen for production of the IL-6 receptor antibody for use in the present invention.

After the gene sequence of IL-6 receptor is inserted into a known expression vector system to transform an

appropriate host cell, the desired IL-6 receptor protein may be purified from the host cell or a culture supernatant thereof using a known method. The purified IL-6 receptor protein thus purified may be used as the sensitizing antigen. Alternatively, cells that are expressing IL-6 receptor or a fusion protein of the IL-6 receptor protein and another protein may be used as the sensitizing antigen.

E. coli that has a plasmid pIBBSF2R containing cDNA encoding human IL-6 receptor has been internationally deposited under the provisions of the Budapest Treaty as HB101-pIBBSF2R on January 9, 1989 with the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, of 1-3, Higashi 1-chome, Tsukuba city, Ibaraki pref., Japan, as FERM BP-2232.

Anti-gp130 antibodies for use in the present invention can be obtained as polyclonal or monoclonal antibodies using a known method. As the anti-gp130 antibodies for use in the present invention, monoclonal antibodies of, in particular, a mammalian origin, are preferred. Monoclonal antibodies of a mammalian origin include those produced by a hybridoma and those produced by a host which has been transformed with an expression vector containing genetically engineered antibody genes. The antibodies, via binding to gp130, inhibit the binding of IL-6/IL-6 receptor complex to gp130, and thereby block the transduction of the biological activity of IL-6 into the cell.

Examples of such antibodies include AM64 antibody (Japanese Unexamined Patent Publication (Kokai) 3(1991)-219894), 4B11 antibody and 2H4 antibody (US 5571513), B-S12 antibody and B-P8 antibody (Japanese Unexamined Patent Publication (Kokai) 8(1996)-291199).

A monoclonal antibody-producing hybridoma can be basically created using a known procedure as described below. Thus, gp130 may be used as a sensitizing antigen

and is immunized in the conventional method of immunization. The immune cells thus obtained are fused with known parent cells in the conventional cell fusion process, and then the monoclonal antibody-producing hybridomas are screened by the conventional screening method to prepare the desired hybridoma.

Specifically, monoclonal antibody may be obtained in the following manner. For example, gp130 used as the sensitizing antigen for antibody generation can be obtained using the gp130 gene sequence/amino acid sequence disclosed in European Patent Application EP 411946.

After a suitable host cell is transformed by inserting the gp130 gene sequence into a known expression vector system, the gp130 protein of interest is purified from the host cell or from the culture supernatant thereof. The purified gp130 receptor protein can be used as the sensitizing antigen. Alternatively, a fusion protein of the gp130 protein and another protein may be used as the sensitizing antigen.

Though mammals to be immunized with the sensitizing antigen are not specifically limited, they are preferably selected in consideration of their compatibility with the parent cell for use in cell fusion. They generally include rodents such as mice, rats, hamsters and the like.

Immunization of animals with a sensitizing antigen is carried out using a known method. A general method, for example, involves the intraperitoneal or subcutaneous administration of a sensitizing antigen to the mammal. Specifically, a sensitizing antigen which has been diluted and suspended in an appropriate amount of phosphate buffered saline (PBS) or physiological saline etc. is mixed, as desired, with an appropriate amount of a common adjuvant, for example Freund's complete adjuvant. After being emulsified, it is preferably administered to a mammal several times every 4 to 21

days. Alternatively a suitable carrier may be used at the time of immunization of the sensitizing antigen.

After immunization and the confirmation of the increase in the desired antibody levels in the serum, the immune cells are taken out from the mammal and are subjected to cell fusion. Preferred immune cells subjected to cell fusion include in particular the spleen cells.

The mammalian myeloma cells as the other parent cells which are subjected to cell fusion with the above-mentioned immune cells preferably include various known cell lines such as P3X63Ag8.653 (Kearney, J. F. et al., J. Immunol. (1979) 123: 1548-1550), P3X63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81: 1-7), NS-1 (Kohler, G. and Milstein, C., Eur. J. Immunol. (1976) 6: 511-519), MPC-11 (Margulies, D.H. et al., Cell (1976) 8: 405-415), SP2/0 (Shulman, M. et al., Nature (1978) 276: 269-270), FO (de St. Groth, S. F. et al., J. Immunol. Methods (1980) 35: 1-21), S194 (Trowbridge, I.S., J. Exp. Med. (1978) 148: 313-323), R210 (Galfre, G. et al., Nature (1979) 277: 131-133) and the like.

Cell fusion between the above immune cells and the myeloma cells may be essentially conducted in accordance with a known method such as that described in Milstein et al. (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73: 3-46).

More specifically, the above cell fusion is carried out in the conventional nutrient broth in the presence of, for example, a cell fusion accelerator. As the cell fusion accelerator, for example, polyethylene glycol (PEG), Sendai virus (HVJ) and the like may be used, and, in addition, an adjuvant such as dimethyl sulfoxide etc. may be added as desired to enhance the efficiency of fusion.

The preferred ratio of the immune cells and the myeloma cells to be used is, for example, 1 to 10 times more immune cells than the myeloma cells. Examples of

culture media to be used for the above cell fusion include RPMI1640 medium and MEM culture medium suitable for the growth of the above myeloma cell lines, and the conventional culture medium used for this type of cell culture, and besides a serum supplement such as fetal calf serum (FCS) may be added.

In cell fusion, predetermined amounts of the above immune cells and the myeloma cells are mixed well in the above culture liquid, to which a PEG solution previously heated to about 37 °C, for example a PEG solution with a mean molecular weight of about 1000 to 6000, is added at a concentration of 30 to 60% (w/v) and mixed to obtain the desired fusion cells (hybridomas). Then, by repeating the sequential addition of a suitable culture liquid and centrifugation to remove the supernatant, cell fusion agents etc. which are undesirable for the growth of the hybridoma can be removed.

Said hybridoma is selected by culturing in the conventional selection medium, for example, the HAT culture medium (a culture liquid containing hypoxanthine, aminopterin, and thymidine). Culturing in said HAT culture medium is continued generally for a period of time sufficient to effect killing of the cells other than the desired hybridoma (non-fusion cells), generally several days to several weeks. The conventional limiting dilution method is conducted in which the hybridomas that produce the desired antibody are screened and monclonally cloned.

In addition to obtaining the above hybridoma by immunizing an animal other than the human with an antigen, it is also possible to sensitize human lymphocytes in vitro with desired antigen or desired antigen-expressing cells, and the resulting sensitized B lymphocytes are fused with a human myeloma cell for example U266, to obtain the desired human antibody having the activity of binding to desired antigen or desired antigen-expressing cells (see Japanese Post-examined



Patent Publication (Kokoku) No. 1(1989)-59878).

Furthermore, a transgenic animal having a repertoire of all human antibody genes is immunized with the antigen or the antigen-expressing cells to obtain the desired human antibody in the method described above (see International Patent Publication WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096 and WO 96/33735).

The monoclonal antibody-producing hybridomas thus constructed can be subcultured in the conventional culture liquid, or can be stored for a prolonged period of time in liquid nitrogen.

In order to obtain monoclonal antibodies from said hybridoma, a method can be used in which said hybridoma is cultured in the conventional method and the antibodies are obtained as the supernatant, or a method in which the hybridoma is administered to and grown in a mammal compatible with said hybridoma and the antibodies are obtained as the ascites. The former method is suitable for obtaining high-purity antibodies, whereas the latter is suitable for a large scale production of antibodies.

Specifically a hybridoma producing anti-IL-6 receptor antibody can be constructed using the method disclosed in Japanese Unexamined Patent Publication (Kokai) 3(1989)-139293. It can be conducted by a method in which the PM-1 antibody-producing hybridoma that was internationally deposited under the provisions of the Budapest Treaty as FERM BP-2998 on July 10, 1990 with the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, of 1-3, Higashi 1-chome, Tsukuba city, Ibaraki pref., Japan, is intraperitoneally injected to BALB/c mice (manufactured by CLEA Japan) to obtain the ascites from which the PM-1 antibody is purified, or a method in which said hybridoma is cultured in a suitable culture medium such as the RPMI1640 medium containing 10% bovine fetal serum and 5% MB-Condimed H1 (manufactured by Boehringer Mannheim), the hybridoma SFM medium (manufactured by GIBCO-BRL), the

PFHM-II medium (manufactured by GIBCO-BRL) and the like, and the PM-1 antibody can be purified from the culture supernatant.

5 A recombinant antibody which was produced by the recombinant gene technology in which an antibody gene was cloned from the hybridoma and integrated into a suitable vector which was then introduced into a host can be used in the present invention as monoclonal antibody (see, for example, Borrebaeck C.A.K., and Larrick J.W. THERAPEUTIC  
10 MONOCLONAL ANTIBODIES, published in the United Kingdom by MACMILLAN PUBLISHERS LTD. 1990).

Specifically, mRNA encoding the variable region (V) of the desired antibody is isolated from antibody-producing cells such as a hybridoma. The isolation of  
15 mRNA is conducted by preparing total RNA using, for example, a known method such as the guanidine ultracentrifuge method (Chirgwin, J.M. et al., Biochemistry (1979) 18, 5294-5299), the AGPC method (Chomczynski, P. et al., Anal. Biochem. (1987) 162, 156-  
20 159), and then mRNA is purified from the total RNA using the mRNA Purification kit (manufactured by Pharmacia) and the like. Alternatively, mRNA can be directly prepared using the Quick Prep mRNA Purification Kit (manufactured by Pharmacia).

25 cdNA of the V region of antibody may be synthesized from the mRNA thus obtained using a reverse transcriptase. cdNA may be synthesized using the AMV Reverse Transcriptase First-strand cdNA Synthesis Kit and the like. Alternatively, for the synthesis and  
30 amplification of cdNA, the 5'-Ampli FINDER RACE Kit (manufactured by Clontech) and the 5'-RACE method (Frohman, M.A. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 8998-9002; Belyavsky, A. et al., Nucleic Acids Res. (1989) 17, 2919-2932) that employs polymerase chain  
35 reaction (PCR) may be used. The desired DNA fragment is purified from the PCR product obtained and may be ligated to vector DNA. Moreover, a recombinant vector is

constructed therefrom and then is introduced into E. coli etc., from which colonies are selected to prepare the desired recombinant vector. The base sequence of the desired DNA may be confirmed by a known method such as the dideoxy method.

Once the DNA encoding the V region of the desired antibody has been obtained, it may be ligated to DNA encoding the constant region (C region) of the desired antibody, which is then integrated into an expression vector. Alternatively, the DNA encoding the V region of the antibody may be integrated into an expression vector which already contains DNA encoding the C region of the antibody.

In order to produce the antibody for use in the present invention, the antibody gene is integrated as described below into an expression vector so as to be expressed under the control of an expression regulatory region, for example an enhancer and/or a promoter. Subsequently, the expression vector may be transformed into a host cell and the antibody can then be expressed therein.

In accordance with the present invention, artificially altered recombinant antibody such as chimeric antibody and humanized antibody can be used for the purpose of lowering heterologous antigenicity against humans. These altered antibodies can be produced using known methods.

Chimeric antibody can be obtained by ligating the thus obtained DNA encoding the V region of antibody to DNA encoding the C region of human antibody, which is then integrated into an expression vector and introduced into a host for production of the antibody therein (see European Patent Application EP 125023, and International Patent Publication WO 92-19759). Using this known method, chimeric antibody useful for the present invention can be obtained.

For example, the plasmid that contains DNA encoding

the L chain V region or the H chain V region of chimeric PM-1 antibody was designated as pPM-K3 or pPM-h1, respectively, and E. coli having the plasmid has been internationally deposited under the provisions of the Budapest Treaty as NCIMB 40366 and NCIMB 40362, respectively, on February 11, 1991 with the National Collections of Industrial and Marine Bacteria Limited.

Humanized antibody which is also called reshaped human antibody has been generated by transplanting the complementarity determining region (CDR) of antibody of a mammal other than the human, for example mouse antibody, into the CDR of human antibody. The general recombinant DNA technology for preparation of such antibodies is also known (see European Patent Application EP 125023 and International Patent Publication WO 92-19759).

Specifically, a DNA sequence which was designed to ligate the CDR of mouse antibody with the framework region (FR) of human antibody is synthesized from several divided oligonucleotides having sections overlapping with one another at the ends thereof. The DNA thus obtained is ligated to the DNA encoding the C region of human antibody and then is integrated into an expression vector, which is introduced into a host for antibody production (see European Patent Application EP 239400 and International Patent Publication WO 92-19759).

For the FR of human antibody ligated through CDR, the complementarity determining region that forms a favorable antigen binding site is selected. When desired, amino acids in the framework region of the antibody variable region may be substituted so that the complementarity determining region of reshaped human antibody may form an appropriate antigen binding site (Sato, K. et al., Cancer Res. (1993) 53, 851-856).

For example, for chimeric antibody or humanized antibody, the C region of human antibody is used. As the C region of human antibody, there can be mentioned C<sub>γ</sub>,

and, for example, Cy1, Cy2, Cy3, and Cy4 can be used. The C region of human antibody may be modified to improve the stability of antibody or the production thereof.

Chimeric antibody consists of the variable region of  
5 antibody derived from a mammal other than the human and the C region derived from human antibody, whereas humanized antibody consists of the complementarity determining region of antibody derived from a mammal other than the human and the framework region and the C  
10 region derived from human antibody. Accordingly, antigenicity thereof in the human body has been reduced so that they are useful as antibody for use in the present invention.

A preferred embodiment of the humanized antibody for  
15 use in the present invention includes humanized PM-1 antibody (see International Patent Publication WO 92-19759).

Antibody genes constructed as described above may be expressed and obtained in a known method. In the case of  
20 mammalian cells, expression may be accomplished using a vector containing a commonly used useful promoter, the antibody gene to be expressed, and DNA in which the poly A signal has been operably linked at 3' downstream thereof or a vector containing said DNA. Examples of the  
25 promoter/enhancer include human cytomegalovirus immediate early promoter/enhancer.

Additionally, as the promoter/enhancer which can be used for expression of antibody for use in the present invention, there are viral promoters/enhancers such as  
30 retrovirus, polyoma virus, adenovirus, and simian virus 40 (SV40), and promoters/enhancers derived from mammalian cells such as human elongation factor 1 $\alpha$  (HEF1 $\alpha$ ).

For example, expression may be readily accomplished by the method of Mulligan et al. (Mulligan, R. C. et al.,  
35 Nature (1979) 277, 108-114) when SV40 promoter/enhancer is used, or by the method of Mizushima et al. (Mizushima,

076250.020001

S. and Nagata, S. Nucleic Acids Res. (1990) 18, 5322)  
when HEFl $\alpha$  promoter/enhancer is used.

In the case of E. coli, expression may be conducted  
by operably linking a commonly used useful promoter, a  
5 signal sequence for antibody secretion, and the antibody  
gene to be expressed, followed by expression thereof. As  
the promoter, for example, there can be mentioned lacZ  
promoter and araB promoter. The method of Ward et al.  
(Ward, E.S. et al., Nature (1098) 341, 544-546; Ward,  
10 E.S. et al., FASEB J. (1992) 6, 2422-2427) may be used  
when lacZ promoter is used, and the method of Better et  
al. (Better, M. et al., Science (1988) 240, 1041-1043)  
may be used when araB promoter is used.

As the signal sequence for antibody secretion, when  
15 produced in the periplasm of E. coli, the pelB signal  
sequence (Lei, S. P. et al., J. Bacteriol. (1987) 169,  
4379-4383) can be used. After separating the antibody  
produced in the periplasm, the structure of the antibody  
is appropriately refolded before use (see, for example,  
20 WO 96/30394).

As the origin of replication, there can be used  
those derived from SV40, polyoma virus, adenovirus,  
bovine papilloma virus (BPV) and the like. Furthermore,  
for the amplification of the gene copy number in the host  
25 cell system, expression vectors can include as selectable  
markers the aminoglycoside phosphotransferase (APH) gene,  
the thymidine kinase (TK) gene, E. coli xanthine  
guaninephosphoribosyl transferase (Ecogpt) gene, the  
dihydrofolate reductase (dhfr) gene and the like.

30 For the production of antibody for use in the  
present invention, any production system can be used.  
The production system of antibody preparation comprises  
the in vitro or the in vivo production system. As the in  
vitro production system, there can be mentioned a  
35 production system which employs eukaryotic cells and the  
production system which employs prokaryotic cells.

When the eukaryotic cells are used, there are the

00762550.020001

production systems which employ animal cells, plant cells, and fungal cells. Known animal cells include (1) mammalian cells such as CHO cells, COS cells, myeloma cells, baby hamster kidney (BHK) cells, HeLa cells, and Vero cells, (2) amphibian cells such as Xenopus oocytes, or (3) insect cells such as sf9, sf21, and Tn5. Known plant cells include, for example, those derived from Nicotiana tabacum, which may be subjected to callus culture. Known fungal cells include yeasts such as the genus Saccharomyces, more specifically Saccharomyces cereviceae, or filamentous fungi such as the genus Aspergillus, more specifically Aspergillus niger.

When the prokaryotic cells are used, there are the production systems which employ bacterial cells. Known bacterial cells include Escherichia coli (E. coli), and Bacillus subtilis.

By introducing via transformation the gene of the desired antibody into these cells and culturing the transformed cells in vitro, the antibody can be obtained. Culturing is conducted by a known method. For example, as the culture liquid, DMEM, MEM, RPMI1640, and IMDM can be used, and serum supplements such as fetal calf serum (FCS) may be used in combination. In addition, antibodies may be produced in vivo by implanting cells into which the antibody gene has been introduced into the abdominal cavity of an animal and the like.

As in vivo production systems, there can be mentioned those which employ animals and those which employ plants. When animals are used, there are the production systems which employ mammals and insects.

As mammals, goats, pigs, sheep, mice, and cattle can be used (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). Also as insects, silkworms can be used. When plants are used, tobacco, for example, can be used.

Antibody genes are introduced into these animals or plants, and the antibodies are produced in such animals

or plants, and recovered. For example, an antibody gene is inserted into the middle of the gene encoding protein which is inherently produced in the milk such as goat  $\beta$  casein to prepare fusion genes. DNA fragments containing the fusion gene into which the antibody gene has been inserted are injected into a goat embryo, and the embryo is introduced into a female goat. The desired antibody is obtained from the milk produced by the transgenic goat borne to the goat who received the embryo or offspring thereof. In order to increase the amount of milk containing the desired antibody produced by the transgenic goat, hormones may be given to the transgenic goat as appropriate. (Ebert, K.M. et al., *Bio/Technology* (1994) 12, 699-702).

When silkworms are used, baculovirus into which the desired antibody gene has been inserted is infected to the silkworm, and the desired antibody can be obtained from the body fluid of the silkworm (Maeda, S. et al., *Nature* (1985) 315, 592-594). Moreover, when tobacco is used, the desired antibody gene is inserted into an expression vector for plants, for example pMON 530, and then the vector is introduced into a bacterium such as *Agrobacterium tumefaciens*. The bacterium is then infected to tobacco such as *Nicotiana tabacum* to obtain the desired antibody from the leaves of the tobacco (Julian, K.-C. Ma et al., *Eur. J. Immunol.* (1994) 24, 131-138).

When antibody is produced in in vitro or in vivo production systems, as described above, DNA encoding the heavy chain (H chain) or the light chain (L chain) of antibody may be separately integrated into an expression vector and the hosts are transformed simultaneously, or DNA encoding the H chain and the L chain may be integrated into a single expression vector and the host is transformed therewith (see International Patent Publication WO 94-11523).

Antibodies for use in the present invention may be



antibody fragments or modified versions thereof as long as they are preferably used. For example, as fragments of antibody, there may be mentioned Fab, F(ab')<sub>2</sub>, Fv or single-chain Fv (scFv) in which Fv's of H chain and L chain were ligated via a suitable linker.

Specifically antibodies are treated with an enzyme, for example, papain or pepsin, to produce antibody fragments, or genes encoding these antibody fragments are constructed, and then introduced into an expression vector, which is expressed in a suitable host cell (see, for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, A.H., Methods in Enzymology (1989) 178, 476-496; Plucktrun, A. and Skerra, A., Methods in Enzymology (1989) 178, 476-496; Lamoyi, E., Methods in Enzymology (1986) 121, 652-663; Rousseaux, J. et al., Methods in Enzymology (1986) 121, 663-669; Bird, R.E. et al., TIBTECH (1991) 9, 132-137).

scFv can be obtained by ligating the V region of H chain and the V region of L chain of antibody. In the scFv, the V region of H chain and the V region of L chain are preferably ligated via a linker, preferably a peptide linker (Huston, J.S. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 5879-5883). The V region of H chain and the V region of L chain in the scFv may be derived from any of the above-mentioned antibodies. As the peptide linker for ligating the V regions, any single-chain peptide comprising, for example, 12-19 amino acid residues may be used.

DNA encoding scFv can be obtained using DNA encoding the H chain or the H chain V region of the above antibody and DNA encoding the L chain or the L chain V region of the above antibody as the template by amplifying the portion of the DNA encoding the desired amino acid sequence among the above sequences by the PCR technique with the primer pair specifying the both ends thereof, and by further amplifying the combination of DNA encoding the peptide linker portion and the primer pair which

defines that both ends of said DNA are ligated to the H chain and the L chain, respectively.

Once DNAs encoding scFv are constructed, an expression vector containing them and a host transformed with said expression vector can be obtained by the conventional methods, and scFv can be obtained using the resultant host by the conventional methods.

These antibody fragments can be produced by obtaining the gene thereof in a similar manner to that mentioned above and by allowing it to be expressed in a host. "Antibody" as used in the claim of the present application encompasses these antibody fragments.

As modified antibodies, antibodies associated with various molecules such as polyethylene glycol (PEG) can be used. "Antibody" as used in the claim of the present application encompasses these modified antibodies. These modified antibodies can be obtained by chemically modifying the antibodies thus obtained. These methods have already been established in the art.

Antibodies produced and expressed as described above can be separated from the inside or outside of the host cell and then may be purified to homogeneity. Separation and purification of the antibody for use in the present invention may be accomplished by affinity chromatography. As the column used for such affinity chromatography, there can be mentioned Protein A column and Protein G column. Examples of the carriers used in the Protein A column are Hyper D, POROS, Sepharose F. F. and the like. Alternatively, methods for separation and purification conventionally used for proteins can be used without any limitation.

Separation and purification of the antibody for use in the present invention may be accomplished by combining, as appropriate, chromatography other than the above-mentioned affinity chromatography, filtration, ultrafiltration, salting-out, dialysis and the like. Chromatography includes, for example, ion exchange

chromatography, hydrophobic chromatography, gel-filtration and the like. These chromatographies can be applied into high performance liquid chromatography (HPLC). Alternatively, reverse-phase HPLC can be used.

5       The concentration of antibody obtained in the above can be determined by the measurement of absorbance or by the enzyme-linked immunosorbent assay (ELISA) and the like. Thus, when absorbance measurement is employed, a sample is appropriately diluted with PBS(-) and then the  
10       absorbance is measured at 280 nm, followed by calculation using the absorption coefficient of 1.35 OD at 1 mg/ml. When the ELISA method is used, measurement is conducted as follows. Thus, 100  $\mu$ l of goat anti-human IgG  
15       (manufactured by TAGO) diluted to 1  $\mu$ g/ml in 0.1 M bicarbonate buffer, pH 9.6, is added to a 96-well plate (manufactured by Nunc), and is incubated overnight at 4  
20       °C to immobilize the antibody. After blocking, 100  $\mu$ l each of appropriately diluted antibody of the present invention or a sample containing the antibody, or 100  $\mu$ l  
of human IgG (manufactured by CAPPEL) as the standard is added, and incubated at room temperature for 1 hour.

After washing, 100  $\mu$ l of 5000-fold diluted alkaline phosphatase-labeled anti-human IgG antibody (manufactured by BIO SOURCE) is added, and incubated at room  
25       temperature for 1 hour. After washing, the substrate solution is added and incubated, followed by the measurement of absorbance at 405 nm using the MICROPLATE READER Model 3550 (manufactured by Bio-Rad) to calculate the concentration of the desired antibody.

30       The altered IL-6 for use in the present invention has an activity of binding to IL-6 receptor and does not transmit the biological activity of IL-6. Thus, the altered IL-6, though it competes with IL-6 receptor for binding to IL-6, does not transmit the biological  
35       activity of IL-6, and thereby it blocks signal

transduction by IL-6.

Altered IL-6 may be constructed through the introduction of mutation by replacing amino acid residues of the amino acid sequence of IL-6. IL-6, the source of  
5 the altered IL-6, may be of any origin, but when the antigenicity is to be considered, it is preferably human IL-6.

Specifically, the secondary structure of IL-6 is predicted using a known molecular modeling program of the amino acid sequence, for example WHATIF (Vriend et al.,  
10 J. Mol. Graphics (1990), 8, 52-56), and the overall effects on the amino acid residue to be replaced is evaluated. After an appropriate amino acid residue was determined, mutation is introduced by the commonly used  
15 polymerase chain reaction (PCR) method using a vector containing the base sequence encoding human IL-6 gene thereby to obtain a gene encoding altered IL-6. This is then integrated, as desired, into an appropriate expression vector, from which altered IL-6 can be  
20 obtained according to the expression, production and purification of said recombinant antibody.

Specific examples of the altered IL-6 are disclosed in Brakenhoff et al., J. Biol. Chem. (1994) 269, 86-93,  
and Savino et al., EMBO J. (1994) 13, 1357-1367, WO 96-  
25 18648, and WO 96-17869.

The IL-6 partial peptide or the IL-6 receptor partial peptide for use in the present invention has an activity of binding to IL-6 receptor or IL-6,  
respectively, and does not transmit the biological  
30 activity of IL-6. Thus, the IL-6 partial peptide or the IL-6 receptor partial peptide binds to IL-6 receptor or IL-6, respectively, and thereby capture it. As a result, they do not transmit the biological activity of IL-6, and block signal transduction of IL-6.

35 The IL-6 partial peptide or the IL-6 receptor partial peptide is a peptide comprising some or all of the amino acid sequence of the region involved in the

09762550.00001

binding to IL-6 and IL-6 receptor in the amino acid sequence of IL-6 or IL-6 receptor. Such a peptide generally comprises 10 - 80, preferably 20 - 50, and more preferably 20 - 40 amino acid residues.

5       The IL-6 partial peptide or the IL-6 receptor partial peptide can be constructed by specifying the region involved in the binding to IL-6 and IL-6 receptor in the amino acid sequence of IL-6 or IL-6 receptor, and by producing some or all of the amino acid sequence by a  
10       conventional method such as a genetic engineering technology or a peptide synthesis method.

15       In order to prepare the IL-6 partial peptide or the IL-6 receptor partial peptide by a genetic engineering technology, the DNA sequence encoding the desired peptide is integrated into an expression vector, from which the peptide can be obtained by the expression, production, and purification of said recombinant antibody.

20       Preparation of the IL-6 partial peptide or the IL-6 receptor partial peptide by the peptide synthesis method can be effected using a method commonly used in peptide synthesis such as the solid phase synthesis or the liquid phase synthesis.

25       Specifically the method described in Zoku-Iyakuhiin no Kaihatsu (Sequel to Development of Pharmaceuticals), Vol. 14, Peptido Gousei (Peptide Synthesis), edited by Haruaki Yajima, Hirokawa Shoten, 1991, may be used. The solid phase synthesis method used includes, for example, a reaction in which an amino acid corresponding to the C-terminal of the peptide to be synthesized is coupled to a  
30       support which is insoluble in organic solvents, and then an amino acid in which an  $\alpha$ -amino group or a side chain functional group has been protected with an appropriate protecting group is condensed one amino acid at a time from the C-terminal to the N-terminal direction, and a  
35       reaction in which said protecting group of the  $\alpha$ -amino group of the amino acid or the peptide coupled to the

resin is eliminated is alternately repeated to elongate the peptide chain. The solid phase peptide synthesis methods are divided into the Boc method and the Fmoc method depending on the type of protecting group to be used.

After the synthesis of the desired peptide is complete, a deprotection reaction and a reaction for cleaving the peptide chain from the support is carried out. For cleavage from the peptide chain, hydrogen fluoride or trifluoromethanesulfonic acid in the Boc method and TFA in the Fmoc method are generally used. In the Boc method, for example, the above peptide resin is treated in hydrogen fluoride in the presence of anisole. Subsequently, the protecting group is eliminated and the peptide is recovered by cleaving from the support. By lyophilizing this, crude peptide can be obtained. On the other hand, in the Fmoc method, TFA, for example, is used in a manner similar to the above to effect the deprotection reaction and the cleavage reaction of the peptide from the support.

The crude peptide thus obtained can be applied to HPLC for its separation and purification. Its elution can be carried out in a water-acetonitrile solvent system that is commonly used for protein purification under an optimum condition. The fraction corresponding to the peak of the profile of the chromatography obtained is collected and lyophilized. The peptide fraction thus purified is identified by subjecting it to the analysis of molecular weight by mass spectroscopic analysis, the analysis of amino acid composition, or the analysis of amino acid sequence, and the like.

Specific examples of the IL-6 partial peptide or the IL-6 receptor partial peptide are disclosed in Japanese Unexamined Patent Publication (Kokai) 2(1990)-188600, Japanese Unexamined Patent Publication (Kokai) 7(1995)-324097, Japanese Unexamined Patent Publication (Kokai) 8(1996)-311098, and United States Patent Publication US

5210075.

5 The activity of the IL-6 antagonist for use in the present invention can be evaluated using a conventionally known method. Specifically, the IL-6-dependent cell  
10 MH60.BSF2 is cultured, to which IL-6 is added, and the activity can be evaluated using the incorporation of <sup>3</sup>H-thymidine into the IL-6-dependent cell in the coexistence of the IL-6 antagonist. Alternatively, evaluation can be  
15 effected by culturing U266, an IL-6 receptor-expressing cell, adding thereto <sup>125</sup>I-labeled IL-6 and an IL-6 antagonist at the same time, and then by determining the <sup>125</sup>I-labeled IL-6 bound to the IL-6 receptor-expressing cell. In the above assay system, a negative control group containing no IL-6 antagonists, in addition to the  
20 group in which an IL-6 receptor antagonist is present, is set up, and the results obtained for them are compared to evaluate the IL-6-inhibiting activity of the IL-6 receptor antagonist.

20 In order to confirm the effects accomplished by the present invention, an IL-6 antagonist for use in the present invention is administered to animals that developed pancreatitis after an overdose of caerulein, and the effect of suppressing pancreatic edema and of improving the weight of the pancreas can be evaluated.  
25 As additional effects of the present invention, there are effects of preventing pancreatitis or the recurrence of pancreatitis.

30 The administration of caerulein to induce pancreatitis, for example, may be carried out according to the method described in the Example below. Animals in which pancreatitis is induced may be those commonly used in experiments such as mice and rats.

35 As described in the Example below, in the animals that developed pancreatitis, the administration of IL-6 receptor antibody resulted in suppression of the pancreas weight and improvement in the edema of the pancreas, and thus it was revealed that IL-6 antagonists such as anti-

IL-6 receptor antibody exert a therapeutic effect on pancreatitis.

The subject to be treated in the present invention is mammals. The subject to be treated is preferably humans.

The preventive or therapeutic agents of the present invention may be administered, either orally or parenterally, systemically or locally. For example, intravenous injection such as drip infusion, intramuscular injection, intraperitoneal injection, subcutaneous injection, suppositories, intestinal lavage, oral enteric coated tablets, and the like can be selected, and the method of administration may be chosen, as appropriate, depending on the age and the conditions of the patient. The effective dosage is chosen from the range of 0.01 mg to 100 mg per kg of body weight per administration. Alternatively, the dosage in the range of 1 to 1000 mg, preferably 5 to 50 mg per patient may be chosen.

The preventive or therapeutic agents for pancreatitis of the present invention may contain pharmaceutically acceptable carriers or additives depending on the route of administration. Examples of such carriers or additives include water, a pharmaceutical acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, gelatin, agar, diglycerin, propylene glycol, polyethylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, a pharmaceutically acceptable surfactant and the like. Additives used are chosen from, but are not limited to, the above or combinations thereof depending on the dosage form.



Examples

The present invention will now be explained in more detail with reference to the examples, reference  
5 examples, and experiments. It should be noted, however, that the present invention is not limited to them in any way.

Example 1.

To B6-hIL-6 transgenic mice or B6 mice (littermates  
10 of hIL-6 T transgenic mice) (Clinical Immunology and Immunopathology, 82: 117-124, 1997), caerulein (manufactured by Kyowa Hakko) dissolved in physiological saline at 50 µg/kg was intraperitoneally given every hour  
15 for 7 times. An anti-mouse IL-6 receptor monoclonal antibody M16-1 was administered to the mice at 1 mg/mouse via the tail vein immediately before caerulein administration.

As the control, the solvent (PBS) for the antibody was used. Eight hours later, the mice were euthanized to  
20 observe the weight of the pancreas, serum amylase, and the histology of the pancreas. The weight of the pancreas and body weight are shown in Figure 1. The histology of the pancreas is shown in Figures 2-4. Serum amylase was measured using the iodo-starch (blue starch)  
25 method. For the histology of the pancreas, a paraffin block of the pancreas was prepared and stained with hematoxylin eosin (HE) stain for microscopic observation.

In the IL-6 transgenic mice, the weight gain of the pancreas induced by caerulein administration was more  
30 pronounced as compared to the litter mate (normal mice).

Visual inspection also revealed that edema was more advanced as well as pancreatitis. By administering MR16-1 to the IL-6 transgenic mice, the weight gain of the  
35 pancreas induced by caerulein administration was suppressed. Histological comparison of the IL-6 transgenic mouse group (Figure 3) and the normal mouse group (Figure 2) has shown that areas of the edema etc.

076550.02001

were smaller in the normal mice and the regions affected by neutrophil infiltration etc. were smaller. This indicates that the administration of MR16-1 resulted in improvement (Figure 4). Thus, since the effect of anti-IL-6 receptor monoclonal antibody was observed in the mouse model of caerulein-induced acute pancreatitis, IL-6 antagonists such as anti-IL-6 receptor antibody are effective, by suppressing the effects of IL-6, in treatment, amelioration of severity, and prevention of onset of acute pancreatitis.

Example 2.

To B6-hIL-6 transgenic mice or B6 mice (littermates of hIL-6 T transgenic mice) (Clinical Immunology and Immunopathology, 82: 117-124, 1997), caerulein (manufactured by Kyowa Hakko) dissolved in physiological saline at 50 µg/kg was intraperitoneally given seven times at hourly intervals. In order to induce severe pancreatitis, LPS (lipopolysaccharide, manufactured by Sigma) was intraperitoneally given at 1 mg/ml concurrently with the initial caerulein administration. Anti-mouse IL-6 receptor monoclonal antibody M16-1 was administered to the mice at 1 mg/mouse via the tail vein 10 minutes before the initial caerulein administration. As the control, the solvent (PBS) for the antibody was used. Eight hours later, the mice were euthanized to measure the weight of the pancreas. The weight of the pancreas and body weight are shown in Figure 5.

In severe pancreatitis induced in the IL-6 transgenic mice, MR16-1 administration caused a pronounced improvement effect. Thus, in the mouse model of severe acute pancreatitis induced by caerulein and LPS, IL-6 antagonists such as anti-IL-6 receptor antibody are effective, by suppressing the effects of IL-6, in treatment, amelioration of severity, and prevention of onset of severe acute pancreatitis.

Reference example 1. Preparation of human soluble IL-6 receptor

Soluble IL-6 receptor was prepared by the PCR method using a plasmid pBSF2R.236 containing cDNA that encodes IL-6 receptor obtained according to the method of Yamasaki et al., (Yamasaki, K. et al., Science (1988) 241, 825-828). Plasmid pBSF2R.236 was digested with a restriction enzyme Sph I to obtain the cDNA of IL-6 receptor, which was then inserted into mpl8 (manufactured by Amersham). Using a synthetic oligoprimers designed to introduce a stop codon into the cDNA of IL-6 receptor, a mutation was introduced into the cDNA of IL-6 receptor by the PCR method using the in vitro Mutagenesis System (manufactured by Amersham). The procedure resulted in the introduction of a stop codon to the amino acid at position 345, and gave cDNA encoding soluble IL-6 receptor.

In order to express the cDNA of soluble IL-6 receptor in CHO cells, it was ligated to plasmid pSV (manufactured by Pharmacia) to obtain plasmid pSVL344. The cDNA of soluble IL-6 receptor that was cleaved with Hind III-Sal I was inserted to plasmid pCEdhfr containing the cDNA of dhfr to obtain plasmid pCEdhfr344 that can be expressed in the CHO cells.

Ten  $\mu$ g of plasmid pCEdhfr344 was transfected to a dhfr-CHO cell line DXB-11 (Urlaub et al., Proc. Natl. Acad. Sci. USA (1980) 77, 4216-4220) by the calcium phosphate precipitation method (Chen C. et al., Mol. Cell. Biol. (1987) 7, 2745-2751). The transfected CHO cells were cultured for 3 weeks in a nucleoside-free  $\alpha$  MEM selection medium containing 1 mM glutamine, 10% dialyzed FCS, 100 U/ml penicillin, and 100  $\mu$ g/ml streptomycin.

The selected CHO cells were screened by the limiting dilution method to obtain a single CHO cell clone. The CHO cell clone was amplified in 20 nM - 200 nM methotrexate (MTX) to obtain a CHO cell line 5E27 that produces human soluble IL-6 receptor. The CHO cell line

5E27 was cultured in an Iscov-modified Dulbecco's medium (IMDM, manufactured by Gibco) containing 5% FBS. The culture supernatant was collected and the concentration of soluble IL-6 receptor in the culture supernatant was determined by ELISA. The result confirmed that soluble IL-6 receptor is present in the culture supernatant.

Reference example 2. Preparation of human IL-6 antibody

Ten  $\mu$ g of the recombinant IL-6 (Hirano et al., Immunol. Lett., 17:41, 1988) was immunized to BALB/c mice together with Freund's complete adjuvant, and this was repeated every week until anti-IL-6 antibody could be detected in the serum. Immune cells were extracted from local lymph node and were then fused with a myeloma cell line P3U1 using polyethylene glycol 1500. Hybridomas were selected according to the method of Oi et al. (Selective Methods in Cellular Immunology, W. H. Freeman and Co., San Francisco, 351, 1980) that employs the HAT medium, and the hybridoma that produces human IL-6 antibody was established.

The hybridoma that produces human IL-6 antibody was subjected to IL-6 binding assay as follows. Thus, a 96-well microtiter plate (manufactured by Dynatech Laboratories, Inc., Alexandria, VA) made of flexible polyvinyl was coated with 100  $\mu$ l of goat anti-mouse Ig (10  $\mu$ l/ml, manufactured by Cooper Biomedical, Inc., Malvern, PA) overnight at 4 °C. Subsequently, the plate was treated with 100  $\mu$ l of PBS containing 1% bovine serum albumin (BSA) at room temperature for 2 hours.

After washing it in PBS, 100  $\mu$ l of the hybridoma culture supernatant was added to each well, and then was incubated overnight at 4 °C. The plate was washed, <sup>125</sup>I-labeled recombinant IL-6 was added to each well to a concentration of 2000 cpm/0.5 ng/well, and then radioactivity of each well after washing was determined by a gamma counter (Beckman Gamma 9000, Beckman

Instruments, Fullerton, CA). Of 216 hybridoma clones, 32 were positive in the IL-6 binding assay. From these clones, stable MH166.BSF2 was finally obtained. Anti-IL-6 antibody MH166 produced by said hybridoma has a subtype of IgG1  $\kappa$ .

Then, the IL-6-dependent mouse hybridoma clone MH60.BSF2 was used to examine a neutralizing activity with respect to the growth of the hybridoma by MH166 antibody. MH60.BSF2 cells were dispensed to  $1 \times 10^4$  /200  $\mu$ l/well, and samples containing MH166 antibody were added thereto, cultured for 48 hours, 0.5  $\mu$ Ci/well of  $^3$ H-thymidine (New England Nuclear, Boston, MA) was added, and the culturing was continued for further 6 hours. The cells were placed on a glass filter paper and were treated by the automatic harvester (Labo Mash Science Co., Tokyo, Japan). As the control, rabbit anti-IL-6 antibody was used.

As a result, MH166 antibody inhibited, in a dose dependent manner, the incorporation of  $^3$ H-thymidine of MH60.BSF2 cells induced by IL-6. This revealed that MH166 antibody neutralizes the activity of IL-6.

Reference example 3. Preparation of human anti-IL-6 receptor antibody

Anti-IL-6 receptor antibody MT18 prepared by the method of Hirata et al. (Hirata, Y. et al. J. Immunol., 143, 2900-2906, 1989) was bound to CNBr-activated Sepharose 4B (manufactured by Pharmacia Fine Chemicals, Piscataway, NJ) according to the attached regimen, and IL-6 receptor (Yamasaki, K. et al., Science (1988) 241, 825-828) was purified. A human myeloma cell line U266 was solubilized with 1 mM p-para-aminophenyl methane sulfonyl fluoride hydrochloride (manufactured by Wako Chemicals) containing 1% digitonin (manufactured by Wako Chemicals), 10 mM triethanolamine (pH 7.8) and 0.15 M NaCl (digitonin buffer), and mixed with MT18 antibody bound to Sepharose 4B beads. Then, the beads were washed

six times with the digitonin buffer to prepare the partially purified IL-6 receptor for use in immunization.

BALB/c mice were immunized four times, at ten-day intervals, with the above partially purified IL-6

5 receptor obtained from  $3 \times 10^9$  U266 cells, and then a hybridoma was prepared using a standard method. The hybridoma culture supernatant from the growth-positive well was tested for its activity of binding to IL-6 receptor according to the method described below.  $5 \times$

10  $10^7$  U266 cells were labeled with  $^{35}\text{S}$ -methionine (2.5 mCi) and were solubilized with the above digitonin buffer. The solubilized U266 cells were mixed with a 0.04 ml volume of MT18 antibody bound to Sepharose 4B beads, and then were washed six times with the digitonin buffer.

15  $^{35}\text{S}$ -methionine-labeled IL-6 receptor was eluted with 0.25 ml of the digitonin buffer (pH 3.4) and was neutralized in 0.025 ml of 1M Tris (pH 7.4).

0.05 ml of the hybridoma culture supernatant was mixed with 0.01ml of Protein G Sepharose (manufactured by Pharmacia). After washing, Sepharose was incubated with 20 0.005 ml of  $^{35}\text{S}$ -labeled IL-6 receptor solution prepared as described above. The immunoprecipitate was analyzed by SDS-PAGE to determine the hybridoma culture supernatant that reacts with IL-6 receptor. As a result, 25 the reaction-positive hybridoma clone PM-1 was established. The antibody produced from the hybridoma PM-1 has a subtype of IgG1k.

The inhibitory activity of IL-6 binding of the antibody produced by the hybridoma PM-1 to human IL-6 30 receptor was studied using the human myeloma cell line U266. A human recombinant IL-6 was prepared from *E. coli* (Hirano et al., Immunol. Lett., 17:41-45, 1988), and was labeled with  $^{125}\text{I}$  using the Bolton-Hunter reagent (New England Nuclear, Boston, MA) (Taga, T. et al., J. Exp. 35 Med. (1987) 166, 967-981).  $4 \times 10^5$  U266 cells were cultured with the culture supernatant of 70% (v/v)

hybridoma PM-1 together with 14,000 cpm of  $^{125}\text{I}$ -labeled IL-6 for one hour. Seventy  $\mu\text{l}$  of the sample was layered on 300  $\mu\text{l}$  FCS in a 400  $\mu\text{l}$  microfuge polyethylene tube. After centrifugation, the radioactivity of the cell was determined.

The result revealed that the antibody produced by the hybridoma PM-1 inhibits the binding of IL-6 to IL-6 receptor.

Reference example 4. Preparation of mouse anti-IL-6 receptor antibody

A monoclonal antibody directed against mouse IL-6 receptor was prepared according to the method described in Saito, et al., J. Immunol. (1993) 147, 168-173.

The CHO cells that produce mouse soluble IL-6 receptor were cultured in the IMDM culture liquid containing 10% FCS. From the culture supernatant, mouse soluble IL-6 receptor was purified using mouse soluble IL-6 receptor antibody RS12 (see Saito, et al., supra) and an affinity column fixed to Affigel 10 gel (manufactured by Biorad).

The mouse soluble IL-6 receptor (50  $\mu\text{g}$ ) thus obtained was mixed with Freund's complete adjuvant, which was then injected to the abdomen of Wistar rats. From 2 weeks after the administration, the animals were boosted with Freund's incomplete adjuvant. On day 45, the rat spleen cells were collected, and the cells at about  $2 \times 10^8$  were fused with  $1 \times 10^7$  mouse myeloma cells P3U1 using a 50% PEG1500 (manufactured by Boehringer Mannheim) according to the conventional method, and then were screened by the HAT culture medium.

After the culture supernatant was added to the plate coated with rabbit anti-rat IgG antibody (manufactured by Cappel), mouse soluble IL-6 receptor was reacted. Subsequently, using rabbit anti-mouse IL-6 receptor antibody and alkaline phosphatase-labeled sheep anti-

rabbit IgG, hybridomas producing antibody directed against mouse soluble IL-6 receptor were screened by ELISA. After antibody production was confirmed, the hybridoma clones were subscreened twice to obtain a single hybridoma clone. The clone was designated as MR16-1.

The neutralizing activity of the antibody produced by the hybridoma on signal transduction of mouse IL-6 was examined by <sup>3</sup>H-thymidine incorporation using MH60.BSF2 cells (Matsuda, T. et al., J. Immunol. (1988) 18, 951-956). To a 96-well plate, MH60.BSF2 cells were prepared at  $1 \times 10^4$  cells/200  $\mu$ l/well. To the plate were added 10 pg/ml mouse IL-6 and MR16-1 antibody or RS12 antibody at 12.3 - 1000 ng/ml, and then were cultured at 37°C and 5% CO<sub>2</sub> for 44 hours and then 1  $\mu$ Ci/well of <sup>3</sup>H-thymidine was added. After 4 hours, the incorporation of <sup>3</sup>H-thymidine was measured. As a result, MR16-1 antibody suppressed the incorporation of <sup>3</sup>H-thymidine of the MH60.BSF2 cells.

Thus, it was demonstrated that the antibody produced by the hybridoma MR16-1 inhibits the binding of IL-6 to IL-6 receptor.

#### Industrial Applicability

In accordance with the present invention, it was shown that IL-6 antagonists such as anti-IL-6 receptor antibody have a therapeutic effect on pancreatitis. Thus, it was demonstrated that IL-6 antagonists are useful as a therapeutic agent for acute pancreatitis and the like.



CLAIMS

1. A preventive or therapeutic agent for pancreatitis comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

5 2. The preventive or therapeutic agent according to claim 1 in which the IL-6 antagonist is an antibody directed against IL-6 receptor.

3. The preventive or therapeutic agent according to claim 2 in which the antibody directed against IL-6  
10 receptor is a monoclonal antibody directed against IL-6 receptor.

4. The preventive or therapeutic agent according to claim 3 in which the antibody directed against IL-6  
15 receptor is a monoclonal antibody directed against human IL-6 receptor.

5. The preventive or therapeutic agent according to claim 3 in which the antibody directed against IL-6  
receptor is a monoclonal antibody directed against mouse  
IL-6 receptor.

20 6. The preventive or therapeutic agent according to any of claims 2 to 5 in which the antibody directed against IL-6 receptor is a recombinant antibody.

7. The preventive or therapeutic agent according to claim 4 in which the monoclonal antibody directed  
25 against human IL-6 receptor is PM-1 antibody.

8. The preventive or therapeutic agent according to claim 5 in which the monoclonal antibody directed against mouse IL-6 receptor is MR16-1 antibody.

9. The preventive or therapeutic agent according to any of claims 2 to 4 in which the antibody directed  
30 against IL-6 receptor is a chimeric antibody or a humanized antibody directed against IL-6 receptor.

10. The preventive or therapeutic agent according to claim 9 in which the humanized antibody directed  
35 against IL-6 receptor is a humanized PM-1 antibody.

11. The preventive or therapeutic agent according to any of claims 1 to 10 in which the pancreatitis is

05762650.000001

acute pancreatitis.

12. An agent for suppressing pancreatic edema said agent comprising an IL-6 antagonist as an active ingredient.

5 13. An agent for suppressing pancreatic edema said agent comprising an antibody directed against IL-6 receptor as an active ingredient.

10 14. A method of preventing or treating pancreatitis which method comprises administering an interleukin-6 (IL-6) antagonist at an amount effective to prevent or treat pancreatitis to the subject in need of such prevention or treatment.

15 15. The preventive or therapeutic method according to claim 14 in which the IL-6 antagonist is an antibody directed against IL-6 receptor.

16 16. The preventive or therapeutic method according to claim 15 in which the antibody directed against IL-6 receptor is a monoclonal antibody directed against IL-6 receptor.

20 17. The preventive or therapeutic method according to claim 16 in which the antibody directed against IL-6 receptor is a monoclonal antibody directed against human IL-6 receptor.

25 18. The preventive or therapeutic method according to claim 16 in which the antibody directed against IL-6 receptor is a monoclonal antibody directed against mouse IL-6 receptor.

30 19. The preventive or therapeutic method according to claim 15 in which the antibody directed against IL-6 receptor is a recombinant antibody.

20. The preventive or therapeutic method according to claim 17 in which the monoclonal antibody directed against human IL-6 receptor is PM-1 antibody.

35 21. The preventive or therapeutic method according to claim 18 in which the monoclonal antibody directed against mouse IL-6 receptor is MR16-1 antibody.

22. The preventive or therapeutic method according

to claim 15 in which the antibody directed against IL-6 receptor is a chimeric antibody or a humanized antibody directed against IL-6 receptor.

23. The preventive or therapeutic method according to claim 22 in which the humanized antibody directed against IL-6 receptor is a humanized PM-1 antibody.

24. The preventive or therapeutic method according to claim 14 in which the pancreatitis is acute pancreatitis.

25. A method of suppressing pancreatic edema in pancreatitis which method comprises administering an IL-6 antagonist to the subject.

26. A method of suppressing pancreatic edema which method comprises administering an antibody directed against IL-6 receptor at an amount effective to prevent or treat pancreatic edema to the subject in need of suppressing pancreatic edema.

27. The use of an interleukin-6 (IL-6) antagonist for the production of a preventive or therapeutic agent for pancreatitis.

28. The use according to claim 27 in which the IL-6 antagonist is an antibody directed against IL-6 receptor.

29. The use according to claim 28 in which the antibody directed against IL-6 receptor is a monoclonal antibody directed against IL-6 receptor.

30. The use according to claim 29 in which the antibody directed against IL-6 receptor is a monoclonal antibody directed against human IL-6 receptor.

31. The use according to claim 29 in which the antibody directed against IL-6 receptor is a monoclonal antibody directed against mouse IL-6 receptor.

32. The use according to any of claims 28 to 31 in which the antibody directed against IL-6 receptor is a recombinant antibody.

33. The use according to claim 30 in which the monoclonal antibody directed against human IL-6 receptor is PM-1 antibody.

34. The use according to claim 31 in which the monoclonal antibody directed against mouse IL-6 receptor is MR16-1 antibody.

5 35. The use according to any of claims 28 to 30 in which the antibody directed against IL-6 receptor is a chimeric antibody or a humanized antibody directed against IL-6 receptor.

10 36. The use according to claim 35 in which the humanized antibody directed against IL-6 receptor is a humanized PM-1 antibody.

37. The use according to any of claims 27 to 36 in which the pancreatitis is acute pancreatitis.

15 38. The use of an IL-6 antagonist for the production of an agent for suppressing pancreatic edema in pancreatitis.

39. The use of antibody directed against IL-6 receptor for the production of an agent for suppressing pancreatic edema in pancreatitis.

076550-2000-1

ABSTRACT

A preventive or therapeutic agent for pancreatitis  
said agent comprising as an active ingredient an  
5 interleukin-6 (IL-6) antagonist such as an antibody  
directed against IL-6 receptor.

09762550.020901

Fig.1




Fig. 2






Fig. 3



09762550.029901


Fig. 4



00762550-020901



Fig. 5



## Declaration and Power of Attorney For Patent Application

## 特許出願宣言書及び委任状

## Japanese Language Declaration

## 日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。 As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A PREVENTIVE OR THERAPEUTIC  
AGENT FOR PANCREATITIS

COMPRISING IL-6 ANTAGONIST  
AS AN ACTIVE INGREDIENT

上記発明の明細書（下記の欄で x 印がついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

☐ 月 日に出発され、米国出願番号または特許協定条約  
国際出願番号を \_\_\_\_\_ とし、  
(該当する場合) \_\_\_\_\_ に訂正されました。

☐ was filed on August 23, 1999  
as United States Application Number or  
PCT International Application Number  
PCT/JP99/04533  
(and was amended on  
\_\_\_\_\_ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第 37 編第 1 条 5.6 項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Japanese Language Declaration  
(日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国外の国の少なくとも一カ国を指定している特許協力条約365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願について外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

外国での先行出願

Priority Claimed

優先権主張

10-251796 (Pat. Appln.) Japan

(Number)

(番号)

(Country)

(国名)

24/August/1998

(Day/Month/Year Filed)

(出願年月日)

☒☐Yes  
はいNo  
いいえ

11-054302 (Pat. Appln.) Japan

(Number)

(番号)

(Country)

(国名)

2/March/1999

(Day/Month/Year Filed)

(出願年月日)

☒☐Yes  
はいNo  
いいえ

私は、第35編米国法典第119条(e)項に基づいて下記の米国外特許出願規定に記載された権利をここに主張いたします。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)

(出願番号)

(Filing Date)

(出願日)

(Application No.)

(出願番号)

(Filing Date)

(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国外特許出願に記載された権利、又は米国を指定している特許協力条約365条(c)に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国外特許出願に開示されていない限り、その先行米国外特許提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.)

(出願番号)

(Filing Date)

(出願日)

(Status: Patented, Pending, Abandoned)

(現況: 特許許可済、係属中、放棄済)

(Application No.)

(出願番号)

(Filing Date)

(出願日)

(Status: Patented, Pending, Abandoned)

(現況: 特許許可済、係属中、放棄済)

私は、自身の知識に基づいて本宣言書で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の表明を行えば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣言を致します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration  
(日本語宣言書)

委任状: 私は下記の発明者として、本出願に関する一切の  
手続を米特許商標局に対して遂行する弁理士または代理人  
として、下記の者を指名いたします。(弁理士、または代理  
人の氏名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint  
the following attorney(s) and/or agent(s) to prosecute this  
application and transact all business in the Patent and Trademark  
Office connected therewith (list name and registration number).

Stephen A. Bent, Reg. No. 29,768  
David A. Blumenthal, Reg. No. 26,257  
William T. Ellis, Reg. No. 26,874  
John J. Feldhaus, Reg. No. 28,822  
Patricia D. Granados, Reg. No. 33,683  
John P. Isacson, Reg. No. 33,715  
Eugene M. Lee, Reg. No. 32,039  
Richard Linn, Reg. No. 25,144  
Peter G. Mack, Reg. No. 26,001

Brian J. McNamara, Reg. No. 32,789  
Sybil Meloy, Reg. No. 22,749  
George E. Quillin, Reg. No. 32,792  
Colin G. Sandercock, Reg. No. 31,298  
Bernhard D. Saxe, Reg. No. 28,665  
Charles F. Schill, Reg. No. 27,590  
Richard L. Schwaab, Reg. No. 25,479  
Arthur Schwartz, Reg. No. 22,115  
Harold C. Wegner, Reg. No. 25,258

## 書類送付先

Send Correspondence to:

Foley & Lardner  
3000 K Street, N.W.  
P.O. Box 25696  
Washington, DC 20007-8696

Foley & Lardner  
3000 K Street, N.W.  
P.O. Box 25696  
Washington, DC 20007-8696

## 直接電話連絡先: (名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

(202)672-5300

(202)672-5300

唯一または第一発明者名	Full name of sole or first inventor <u>Akihiro Panakoshi</u>	
発明者の署名	日付	Inventor's signature <u>Akihiro Panakoshi</u> Date <u>January 22, 2001</u>
住所	Residence <u>Fukuoka-shi, Fukuoka, Japan</u> <u>JPX</u>	
国籍	Citizenship <u>Japanese</u>	
私書箱	Post Office Address <u>28-33, Wakahisa 6-chome,</u>	
	<u>Minami-ku, Fukuoka-shi, Fukuoka 815-0042, Japan</u>	
第二共同発明者	Full name of second joint inventor, if any <u>Kyoko Miyasaka</u>	
第二共同発明者の署名	日付	Second inventor's signature <u>Kyoko Miyasaka</u> Date <u>January 22, 2001</u>
住所	Residence <u>Setagaya-ku, Tokyo, Japan</u> <u>JPX</u>	
国籍	Citizenship <u>Japanese</u>	
私書箱	Post Office Address <u>5-13, Hanegi 2-chome,</u>	
	<u>Setagaya-ku, Tokyo 156-0042, Japan</u>	

(第三以降の共同発明者についても同様に記載し、署名をす  
ること)

(Supply similar information and signature for third and  
subsequent joint inventors.)